Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiao Cai, Ling Qiu, Lei Ma, Nan Zhang, Fang-yi Fan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	plasmablastic lymphoma bortezomib lenalidomide autologous hematopoietic stem cell transplantation 18F-FDG PET/CT Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0b1136c191e8499ba4a5fd84606a74a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b1136c191e8499ba4a5fd84606a74a7
record_format	dspace
spelling	oai:doaj.org-article:0b1136c191e8499ba4a5fd84606a74a72021-12-03T05:06:29ZCase Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma2296-858X10.3389/fmed.2021.749863https://doaj.org/article/0b1136c191e8499ba4a5fd84606a74a72021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.749863/fullhttps://doaj.org/toc/2296-858XThe standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.Jiao CaiLing QiuLei MaNan ZhangFang-yi FanFrontiers Media S.A.articleplasmablastic lymphomabortezomiblenalidomideautologous hematopoietic stem cell transplantation18F-FDG PET/CTMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	plasmablastic lymphoma bortezomib lenalidomide autologous hematopoietic stem cell transplantation 18F-FDG PET/CT Medicine (General) R5-920
spellingShingle	plasmablastic lymphoma bortezomib lenalidomide autologous hematopoietic stem cell transplantation 18F-FDG PET/CT Medicine (General) R5-920 Jiao Cai Ling Qiu Lei Ma Nan Zhang Fang-yi Fan Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
description	The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.
format	article
author	Jiao Cai Ling Qiu Lei Ma Nan Zhang Fang-yi Fan
author_facet	Jiao Cai Ling Qiu Lei Ma Nan Zhang Fang-yi Fan
author_sort	Jiao Cai
title	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
title_short	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
title_full	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
title_fullStr	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
title_full_unstemmed	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
title_sort	case report: bortezomib plus cdop followed by sequential autologous hematopoietic stem cell transplantation and lenalidomide-based maintenance therapy in plasmablastic lymphoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0b1136c191e8499ba4a5fd84606a74a7
work_keys_str_mv	AT jiaocai casereportbortezomibpluscdopfollowedbysequentialautologoushematopoieticstemcelltransplantationandlenalidomidebasedmaintenancetherapyinplasmablasticlymphoma AT lingqiu casereportbortezomibpluscdopfollowedbysequentialautologoushematopoieticstemcelltransplantationandlenalidomidebasedmaintenancetherapyinplasmablasticlymphoma AT leima casereportbortezomibpluscdopfollowedbysequentialautologoushematopoieticstemcelltransplantationandlenalidomidebasedmaintenancetherapyinplasmablasticlymphoma AT nanzhang casereportbortezomibpluscdopfollowedbysequentialautologoushematopoieticstemcelltransplantationandlenalidomidebasedmaintenancetherapyinplasmablasticlymphoma AT fangyifan casereportbortezomibpluscdopfollowedbysequentialautologoushematopoieticstemcelltransplantationandlenalidomidebasedmaintenancetherapyinplasmablasticlymphoma
_version_	1718373912438374400

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

Ejemplares similares